MultiplexDX at ASCO 2026: Connecting Science, Innovation, and the Future of Cancer Care
MultiplexDX at ASCO 2026: Connecting Science, Innovation, and the Future of Cancer Care
MultiplexDX International is proud to be represented at the ASCO 2026 Annual Meeting in Chicago, one of the most influential global gatherings in oncology — a place “where groundbreaking science, innovation, and connection come together to shape the future of cancer care.”
Our leadership team — Pavol Čekan, Evan Paul and Rolando Brawer — is engaging with the international oncology community, meeting with clinicians, researchers, industry leaders and strategic partners to advance meaningful conversations around precision diagnostics, translational research and the future clinical potential of Multiplex8+.
Our presence at ASCO reflects an important part of our mission: building the right scientific, clinical and commercial connections to help bring Slovak innovation closer to patients worldwide.
We are proud to represent MultiplexDX — and Slovakia — in a global environment where the future of cancer care is being actively shaped.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
